Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A43196 | 32333822 | Liver Int | Impact of Helicobacter pylori-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk. | 2020 | Details |
| A43197 | 32331890 | J Dairy Sci | Sirtuin 3 improves fatty acid metabolism in response to high nonesterified fatty acids in calf hepatocytes by modulating gene expression. | 2020 | Details |
| A43198 | 32328144 | Evid Based Complement Alternat Med | Corrigendum to "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease". | 2020 | Details |
| A43199 | 32320741 | Metabolism | Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. | 2020 | Details |
| A43200 | 32318746 | J Mol Med (Berl) | Fructose metabolism by the guts cuts liver fat. | 2020 | Details |
| A43201 | 32316687 | Nutrients | Shikonin Attenuates Hepatic Steatosis by Enhancing Beta Oxidation and Energy Expenditure via AMPK Activation. | 2020 | Details |
| A43202 | 32314485 | Liver Transpl | Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors. | 2020 | Details |
| A43203 | 32306495 | Liver Int | Potential implications of COVID-19 in non-alcoholic fatty liver disease. | 2020 | Details |
| A43204 | 32302525 | Gastroenterology | Nonalcoholic Fatty Liver Disease in 2020. | 2020 | Details |
| A43205 | 32291744 | Eur J Clin Invest | Publicly stressing the role of mitochondria in NAFLD with(in) a sports event. | 2020 | Details |
| A43206 | 32284341 | Cancer Epidemiol Biomarkers Prev | Association between Dietary Tomato Intake and the Risk of Hepatocellular Carcinoma: The Singapore Chinese Health Study. | 2020 | Details |
| A43207 | 32283879 | Minerva Gastroenterol Dietol | Non-alcoholic fatty liver disease and primary care physicians. | 2020 | Details |
| A43208 | 32282399 | Eur J Gastroenterol Hepatol | Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. | 2021 | Details |
| A43209 | 32280051 | J Hepatol | Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". | 2020 | Details |
| A43210 | 32278005 | J Hepatol | Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. | 2020 | Details |
| A43211 | 32277896 | Lancet Gastroenterol Hepatol | Redefining non-alcoholic fatty liver disease: what's in a name? | 2020 | Details |
| A43212 | 32276730 | J Hepatol | FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A43213 | 32275777 | Hepatology | FXR Agonists as Therapy for Liver Disease. | 2020 | Details |
| A43214 | 32274349 | J Clin Transl Hepatol | Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. | 2019 | Details |
| A43215 | 32273138 | J Hepatol | NAFLD referral patterns in a large US academic center. | 2020 | Details |
| A43216 | 32272823 | Minerva Gastroenterol (Torino) | One-minute liver "digitopsy" for point of care risk stratification of fibrosis in nonalcoholic fatty liver disease. | 2020 | Details |
| A43217 | 32272819 | Clin Mol Hepatol | Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? | 2020 | Details |
| A43218 | 32269328 | Nat Rev Gastroenterol Hepatol | Intestinal gluconeogenesis prevents hepatic steatosis. | 2020 | Details |
| A43219 | 32266419 | Arch Toxicol | COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? | 2020 | Details |
| A43220 | 32265051 | J Hepatol | Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". | 2020 | Details |
| A43221 | 32258950 | Hepatol Commun | Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. | 2020 | Details |
| A43222 | 32255570 | Liver Int | HSD17B13 as a promising therapeutic target against chronic liver disease. | 2020 | Details |
| A43223 | 32255299 | Clin Lab | Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. | 2020 | Details |
| A43224 | 32251015 | Clin Transl Gastroenterol | Correction to: Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43225 | 32247247 | J Trace Elem Med Biol | Epidemiology, risk factors across the spectrum of age-related metabolic diseases. | 2020 | Details |
| A43226 | 32245907 | Gut | Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. | 2020 | Details |
| A43227 | 32241600 | Gastroenterol Hepatol | Bibliometric analysis of the 100 most-cited articles in the field of hepatology. | 2020 | Details |
| A43228 | 32239856 | Zhongguo Ying Yong Sheng Li Xue Za Zhi | [Effects of Salvia mil on Th17 cells and related cytokines in non-alcoholic fatty liver disease]. | 2019 | Details |
| A43229 | 32234536 | Gastroenterology | Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. | 2020 | Details |
| A43230 | 32229664 | J Basic Clin Physiol Pharmacol | Altered composition of high-lipid diet may generate reactive oxygen species by disturbing the balance of antioxidant and free radicals. | 2020 | Details |
| A43231 | 32229039 | J Hepatol | Caveats for the implementation of global strategies against non-alcoholic fatty liver disease. | 2020 | Details |
| A43232 | 32229037 | J Hepatol | Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A43233 | 32222994 | Hepatology | Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression? | 2020 | Details |
| A43234 | 32222527 | Exp Parasitol | The acute schistosomiasis mansoni ameliorates metabolic syndrome in the C57BL/6 mouse model. | 2020 | Details |
| A43235 | 32220903 | Gut | Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts? | 2020 | Details |
| A43236 | 32220558 | Cell Mol Gastroenterol Hepatol | Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis. | 2020 | Details |
| A43237 | 32219876 | Hepatology | Reply. | 2020 | Details |
| A43238 | 32218771 | Front Endocrinol (Lausanne) | Editorial: Metabolic Health in Normal and Abnormal Sleep. | 2020 | Details |
| A43239 | 32212018 | Dig Dis Sci | Correction to: Omega‑3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43240 | 32205228 | Food Chem Toxicol | Blood BTEXS and heavy metal levels are associated with liver injury and systemic inflammation in Gulf states residents. | 2020 | Details |
| A43241 | 32201259 | Am J Pathol | Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice. | 2020 | Details |
| A43242 | 32199879 | Gastroenterology | Clinical and Genetic Markers of Nonalcoholic Fatty Liver Disease and Prediction of Liver Disease Mortality: Ready for Population Screening? | 2020 | Details |
| A43243 | 32199846 | JACC Cardiovasc Imaging | Prognostic Value of Coronary Computed Tomographic Angiography in Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43244 | 32192316 | Clin Mol Hepatol | Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A43245 | 32192273 | Clin Mol Hepatol | Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis? | 2020 | Details |
| A43246 | 32184272 | Diabetes | Branched-Chain Amino Acids Exacerbate Obesity-Related Hepatic Glucose and Lipid Metabolic Disorders via Attenuating Akt2 Signaling. | 2020 | Details |
| A43247 | 32182638 | J Obes Metab Syndr | Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43248 | 32181687 | DNA Cell Biol | DES1: A Key Driver of Lipotoxicity in Metabolic Disease. | 2020 | Details |
| A43249 | 32178487 | Clin Mol Hepatol | Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma. | 2020 | Details |
| A43250 | 32174092 | J Obes Metab Syndr | Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38). | 2020 | Details |
| A43251 | 32171039 | Hepatology | MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis. | 2020 | Details |
| A43252 | 32160729 | Clin Mol Hepatol | Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? | 2020 | Details |
| A43253 | 32146692 | Diabetes Ther | Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition. | 2020 | Details |
| A43254 | 32145091 | Hepatology | Mutations in the V-ATPase Assembly Factor VMA21 Cause a Congenital Disorder of Glycosylation With Autophagic Liver Disease. | 2020 | Details |
| A43255 | 32143834 | Rev Clin Esp (Barc) | Clinical ultrasonography in cardiovascular risk. | 2020 | Details |
| A43256 | 32140493 | Hepatobiliary Surg Nutr | Independent regulation of tumorigenesis and fibrosis in non-alcoholic fatty liver disease. | 2020 | Details |
| A43257 | 32140409 | IDCases | Invasive pulmonary aspergillosis in a patient with cirrhosis. | 2020 | Details |
| A43258 | 32132415 | Curr Opin Lipidol | Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease. | 2020 | Details |
| A43259 | 32130411 | Inflamm Bowel Dis | Response to "Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease". | 2020 | Details |
| A43260 | 32130410 | Inflamm Bowel Dis | Reply to the Letter to the Editor: Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. | 2020 | Details |
| A43261 | 32124336 | MMW Fortschr Med | [Non-alcoholic fatty liver disease (NAFLD)]. | 2020 | Details |
| A43262 | 32122723 | J Hepatol | β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis. | 2020 | Details |
| A43263 | 32121065 | Cells | Relationship between Heart Disease and Liver Disease: A Two-Way Street. | 2020 | Details |
| A43265 | 32120400 | Ann Intern Med | Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. | 2020 | Details |
| A43266 | 32118303 | Hepatology | Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. | 2020 | Details |
| A43267 | 32118004 | Front Med (Lausanne) | Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients. | 2020 | Details |
| A43268 | 32109931 | Eur J Gastroenterol Hepatol | Homeostasis model assessment of insulin resistance and lobular inflammation in nondiabetic patients with nonalcoholic fatty liver disease: methodological considerations. | 2020 | Details |
| A43269 | 32107896 | Minerva Cardioangiol | Non-alcoholic fatty liver disease and heart valve disease: a neglected link. | 2020 | Details |
| A43270 | 32107051 | J Hepatol | Two cases of non-alcoholic fatty liver disease caused by biallelic ABHD5 mutations. | 2020 | Details |
| A43271 | 32104916 | Hepatology | Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis? | 2020 | Details |
| A43272 | 32101094 | Radiology | Fatty Liver Disease: Artificial Intelligence Takes on the Challenge. | 2020 | Details |
| A43273 | 32100348 | Aliment Pharmacol Ther | Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Authors' reply. | 2020 | Details |
| A43274 | 32100347 | Aliment Pharmacol Ther | Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. | 2020 | Details |
| A43275 | 32093271 | Int J Mol Sci | A Rare Mutation in The APOB Gene Associated with Neurological Manifestations in Familial Hypobetalipoproteinemia. | 2020 | Details |
| A43276 | 32087105 | Am J Med | A Confusing Picture: Refractory Encephalopathy Complicating Nonalcoholic Steatohepatitis. | 2020 | Details |
| A43277 | 32086945 | Hepatology | Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Human Alcoholic Liver Disease. | 2020 | Details |
| A43278 | 32086769 | Pharmacoeconomics | We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. | 2020 | Details |
| A43281 | 32072735 | Diabetes Obes Metab | Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. | 2020 | Details |
| A43282 | 32071435 | Nat Rev Mol Cell Biol | AMPK against NASH. | 2020 | Details |
| A43283 | 32070159 | J Int Med Res | Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. | 2020 | Details |
| A43284 | 32069155 | Diabetes Technol Ther | NAFLD/NASH and Diabetes. | 2020 | Details |
| A43285 | 32068704 | Nursing | Nonalcoholic fatty liver disease: What nurses need to know. | 2020 | Details |
| A43286 | 32064764 | Liver Int | Childhood obesity and adult non-alcoholic fatty liver disease. | 2020 | Details |
| A43287 | 32061110 | J Pineal Res | Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies. | 2020 | Details |
| A43288 | 32060128 | Gut | Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? | 2020 | Details |
| A43289 | 32057684 | Dig Liver Dis | Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. | 2020 | Details |
| A43290 | 32050066 | J Chem Inf Model | Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. | 2020 | Details |
| A43291 | 32048880 | Future Med Chem | Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs. | 2020 | Details |
| A43292 | 32045516 | J Obes Metab Syndr | Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38). | 2020 | Details |
| A43293 | 32043611 | Hepatology | Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43294 | 32043278 | Hepatology | Reply. | 2020 | Details |
| A43295 | 32039490 | Hepatology | NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse. | 2020 | Details |
| A43296 | 32037049 | Am J Surg | Discussion on: Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis. | 2019 | Details |
| A43297 | 32033769 | Gastroenterol Clin North Am | Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43298 | 32033768 | Gastroenterol Clin North Am | Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Disease Burden Grows. | 2020 | Details |